The latest price target for Legend Biotech (NASDAQ:LEGN) was reported by UBS on June 3, 2026. The analyst firm set a price target for $49.00 expecting LEGN to rise to within 12 months (a possible 73.57% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Legend Biotech (NASDAQ:LEGN) was provided by UBS, and Legend Biotech maintained their buy rating.

The last upgrade for Legend Biotech Corp happened on April 17, 2024 when Scotiabank raised their price target to $65. Scotiabank previously had a sector perform for Legend Biotech Corp.

The last downgrade for Legend Biotech Corp happened on January 22, 2026 when TD Cowen changed their price target from $62 to $21 for Legend Biotech Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Legend Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Legend Biotech was filed on June 3, 2026 so you should expect the next rating to be made available sometime around June 3, 2027.

While ratings are subjective and will change, the latest Legend Biotech (LEGN) rating was a maintained with a price target of $31.00 to $49.00. The current price Legend Biotech (LEGN) is trading at is $28.23, which is out of the analyst’s predicted range.